TD Cowen Bets on UnitedHealth and Humana Comebacks
TD Cowen upgraded UnitedHealth (UNH) and Humana (HUM) to Buy, citing Medicare Advantage plan changes. UNH's price target raised to $455, HUM to $485. Analyst sees UNH EPS growth mid-to-high teens through 2028. HUM's 2028 EPS forecast at $40.42. Upgrades depend on margin recovery and member retention.
How this was made
The 30-second read
Why it matters
The upgrades provide a clear catalyst for short‑term price moves, especially in pre‑market trading.
Market read
Analyst upgrades with higher price targets are likely to drive immediate buying interest in both stocks.
What to watch
Potential competitive pressure from new entrants and macro‑economic headwinds on discretionary health spending.
Background
TD Cowen issued fresh upgrades for UnitedHealth and Humana, citing Medicare Advantage plan changes and margin recovery.
Ticker impact
TD Cowen upgraded UnitedHealth Group to Buy and raised its price target to $455, prompting pre‑market price gains.
likely upward pressure as investors price in the upgraded rating and higher target.
Analyst cites Medicare Advantage changes and Optum Health recovery as catalysts, providing a concrete thesis.
TD Cowen upgraded Humana to Buy, lifted its price target to $485 and kept its 2028 EPS forecast at $40.42.
likely upward pressure as the market absorbs the upgraded outlook and target.
Analyst highlights Medicare Advantage margin recovery and higher out‑of‑pocket limits as drivers.
Market effects
Both upgrades may lift health‑care insurers and related Medicare Advantage providers.
U.S. health‑care sector could see modest gains in early trading.
Limited to U.S. markets; no direct global impact.
Counterpoint
The upgrades assume Medicare Advantage reforms will boost margins, but regulatory risk or slower Optum recovery could limit upside.
Key entities
- analystTD Cowen
Research firm that issued the upgrades.
- companyUnitedHealth Group
Health insurer upgraded to Buy.
- companyHumana
Health insurer upgraded to Buy.


